Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Repeated Hyperarc Radiosurgery for Recurrent Intracranial Metastases and Dosimetric Analysis of Recurrence Pattern to Account for Diffuse Dose Effect on Microscopical Disease Publisher



Nicosia L1 ; Allegra AG1 ; Giajlevra N1 ; Bayani R2, 3 ; Darzikolaee NM3 ; Mazzola R1 ; Pastorello E1 ; Ravelli P1 ; Ricchetti F1 ; Rigo M1 ; Ruggieri R1 ; Gurrera D1 ; Borgese RF1 ; Gaito S4, 5 Show All Authors
Authors
  1. Nicosia L1
  2. Allegra AG1
  3. Giajlevra N1
  4. Bayani R2, 3
  5. Darzikolaee NM3
  6. Mazzola R1
  7. Pastorello E1
  8. Ravelli P1
  9. Ricchetti F1
  10. Rigo M1
  11. Ruggieri R1
  12. Gurrera D1
  13. Borgese RF1
  14. Gaito S4, 5
  15. Minniti G6, 7
  16. Navarria P8, 9
  17. Scorsetti M8, 9
  18. Alongi F1, 10
Show Affiliations
Authors Affiliations
  1. 1. Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Negrar, 37024, Italy
  2. 2. Radiation Oncology Department, Hamadan University of Medical Sciences, Hamadan, Iran
  3. 3. Radiation Oncology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Division of Clinical Cancer Science, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
  5. 5. Department of Proton Beam Therapy, The Christie Proton Beam Therapy Centre, Manchester, United Kingdom
  6. 6. Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University, Rome, Italy
  7. 7. IRCCS Neuromed, Pozzilli, Italy
  8. 8. Department of Biomedical Sciences, Humanitas University, Milan, Pieve Emanuele, 20090, Italy
  9. 9. Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Via Manzoni 56, Milan, Rozzano, 20089, Italy
  10. 10. University of Brescia, Brescia, Italy

Source: Clinical and Translational Radiation Oncology Published:2024


Abstract

Aims: Evaluate effectiveness and safety of multiple HyperArc courses and patterns of progression in patients affected by BMs with intracranial progression. Methods: 56 patients were treated for 702 BMs with 197 (range 2–8) HyperArc courses in case of exclusive intracranial progression. Primary end-point was the overall survival (OS), secondary end-points were intracranial progression-free survival (iPFS), toxicity, local control (LC), neurological death (ND), and whole-brain RT (WBRT)-free survival. Site of progression was evaluated against isodoses levels (0, 1, 2, 3, 5, 7, 8, 10, 13, 15, 20, and 24 Gy.). Results: The 1-year OS was 70 %, and the median was 20.8 months (17–36). At the univariate analysis (UVA) biological equivalent dose (BED) > 51.3 Gy and non-melanoma histology significantly correlated with OS. The median time to iPFS was 4.9 months, and the 1-year iPFS was 15 %. Globally, 538 new BMs occurred after the first HA cycle in patients with extracranial disease controlled. 96.4 % of them occurred within the isodoses range 0–7 Gy as follows: 26.6 % (0 Gy), 16.5 % (1 Gy), 16.5 % (2 Gy), 20.1 % (3 Gy), 13.1 % (5 Gy), 3.4 % (7 Gy) (p = 0.00). Radionecrosis occurred in 2 metastases (0.28 %). No clinical toxicity of grade 3 or higher occurred during follow-up. One- and 2-year LC was 90 % and 79 %, respectively. At the UVA BED > 70 Gy and non-melanoma histology were significant predictors of higher LC. The 2-year WBRT-free survival was 70 %. After a median follow-up of 17.4 months, 12 patients deceased by ND. Conclusion: Intracranical relapses can be safely and effectively treated with repeated HyperArc, with the aim to postpone or avoid WBRT. Diffuse dose by volumetric RT might reduce microscopic disease also at relatively low levels, potentially acting as a virtual CTV. Neurological death is not the most common cause of death in this population, which highlights the impact of extracranial disease on overall survival. © 2024 The Author(s)